Literature DB >> 14980929

Intrathecal and oral clonidine as prophylaxis for postoperative alcohol withdrawal syndrome: a randomized double-blinded study.

I Dobrydnjov1, K Axelsson, L Berggren, J Samarütel, B Holmström.   

Abstract

UNLABELLED: In this study, we evaluated the effect of intrathecal and oral clonidine as supplements to spinal anesthesia with lidocaine in patients at risk of postoperative alcohol withdrawal syndrome (AWS). We hypothesized that clonidine would have a prophylactic effect on postoperative AWS. Forty-five alcohol-dependent patients (daily ethanol intake >60 g) scheduled for transurethral resection of the prostate were double-blindly randomized into three groups. All patients received hyperbaric lidocaine 100 mg intrathecally. The diazepam group (DiazG) was premedicated with diazepam 10 mg orally; the intrathecal clonidine group (Clon(i/t)G) received a placebo (saline) tablet and clonidine 150 microg intrathecally; and the oral clonidine group (Clon(p/o)G) received clonidine 150 microg orally. For patients diagnosed with AWS, the Clinical Institute Withdrawal Assessment for Alcohol, revised scale, was used. Twelve patients in the DiazG had symptoms of AWS, compared with two in the Clon(i/t)G and one in the Clon(p/o)G. The median Clinical Institute Withdrawal Assessment for Alcohol, revised scale, score was 12 in the DiazG versus 1 in the clonidine-treated groups. Two patients in the DiazG had severe delirium. Patients receiving oral clonidine had a slightly decreased mean arterial blood pressure 6-12 h after spinal anesthesia (P < 0.05); patients in the DiazG had a hyperdynamic circulatory reaction 24-72 h after surgery. In conclusion, preoperative clonidine 150 microg, intrathecally or orally, prevented significant postoperative AWS in ethanol-dependent patients. IMPLICATIONS: In this randomized, double-blinded study, clonidine 150 microg both intrathecally and orally prevented postoperative alcohol-withdrawal symptoms in alcohol-dependent men. The effect was superior to that with a single dose of diazepam 10 mg orally.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980929     DOI: 10.1213/01.ane.0000099719.97261.da

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Current approaches to the recognition and treatment of alcohol withdrawal and delirium tremens: "old wine in new bottles" or "new wine in old bottles".

Authors:  Theodore A Stern; Anne F Gross; Thomas W Stern; Shamim H Nejad; Jose R Maldonado
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Retrospective Review of Critically Ill Patients Experiencing Alcohol Withdrawal: Dexmedetomidine Versus Propofol and/or Lorazepam Continuous Infusions.

Authors:  Kimberly A Ludtke; Kevin S Stanley; Natalie L Yount; Richard D Gerkin
Journal:  Hosp Pharm       Date:  2015-03

3.  Dexmedetomidine use in the setting of cocaine-induced hypertensive emergency and aortic dissection: a novel indication.

Authors:  Fahad Javed; Alexandre Miguel Benjo; Kiran Reddy; Muhammad Shoaib Akram; Shahzeb Afsar Khan; Manpreet Singh Sabharwal; Girish Nadkarni; Emad F Aziz; Eyal Herzog
Journal:  Case Rep Med       Date:  2011-09-26

4.  Clonidine improved laboratory-measured decision-making performance in abstinent heroin addicts.

Authors:  Xiao-Li Zhang; Gui-Bin Wang; Li-Yan Zhao; Li-Li Sun; Jun Wang; Ping Wu; Lin Lu; Jie Shi
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

5.  Alcoholic delirium tremens with hollow viscus perforation scheduled for emergency laparotomy.

Authors:  Anand T Talikoti; Bs Sindhu; Sp Kavyashree; Ks Kishore Kumar
Journal:  Indian J Anaesth       Date:  2012-03

6.  The Sedative Effect of Propranolol on Critically Ill Patients: A Case Series.

Authors:  Junji Shiotsuka; Andrew Steel; James Downar
Journal:  Front Med (Lausanne)       Date:  2017-05-04

7.  Adjuvants to local anesthetics: Current understanding and future trends.

Authors:  Amlan Swain; Deb Sanjay Nag; Seelora Sahu; Devi Prasad Samaddar
Journal:  World J Clin Cases       Date:  2017-08-16       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.